CRISPR/Cas9 Application in CAR-T Cell Based Tumor Therapies
DOI:
https://doi.org/10.54097/1v02kg41Keywords:
CRISPR/Cas9 system, CAR-T cell, tumor therapies.Abstract
The CRISPR/Cas9 system is an essential tool for treating cancer. In this paper, CRISPR/Cas9 homogenic orientation repair (HDR), NHEJ (NHEJ) and the DNA repair mechanism are discussed in this paper. Furthermore, CRISPR/Cas9 has been applied to CAR-T cells genetically modified, focusing on improvements in expression, survival, and the manner in which CAR-T cells operate, as well as their success against cancer cells. This article, we review CAR-T therapeutic approaches and their challenges in both solid and hematological malignancies. Utilizing CRISPR/Cas9 can address this issue by optimizing CAR structure, enhancing cell survival and enhancing CAR-T targeting ability. Problems related to cytotoxicity, targeting specificity, and safety remain. In this article, we suggest the optimization of CRISPR/Cas9 transmission, selection of appropriate target genes, and implementation of security surveillance and assessment. To conclude, CRISPR/Cas9 therapy may enhance efficacy and offer promising prospects for CAR-T carcinoma. But more research and experience is needed to make sure that it is safe and effective.
Downloads
References
ZHU Xiaofei, HUANG Jiaomei, YUAN Hao, WAN Yi. Methods for Discovery and Analysis of Class2 CRISPR-Cas Systems[J]. Journal of Tropical Biology, 2021, 12(1): 115-123.
Makarova K S, Haft D H, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems[J]. Nature Reviews Microbiology, 2011, 9[7]: 467-477.
Chylinski K, Makarova K S, Charpentier E, et al. Classification and evolution of CRISPR-Cas systems[J]. Nature Reviews Microbiology, 2014, 12[3]: 653-661.
Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
Mali, P., Esvelt, K. M., & Church, G. M. (2013). Cas9 as a versatile tool for engineering biology. Nature Methods, 10[11], 957-963.
Kanchiswamy, C. N., Maffei, M. E., & Malnoy, M. (2016). Non-host disease resistance response in grapefruit to the Asian citrus psyllid and its associated bacterium Candidatus Liberibacter asiaticus. BMC Genomics, 17[2], 1-14.
Shen, B., Zhang, X., Du, Y., & Wang, J. (2014). Monogenic genetic trait modifications mediated by zinc finger nucleases in rice and wheat. Proceedings of the National Academy of Sciences, 111(47), 16579-16584.
Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-117.
Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3[5]:388-398.
Ma JSY, Kim JY, Kazane SA, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113[5]:E450-E458.
Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23[10]:2255-2266.
Eyquem J, Mansilla-Soto J, van der Stegen SJC, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-117.
Hay KA, Turtle CJ. Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. Drugs. 2017;77[4]:237-245.
Perna F, Berman SH, Soni RK, et al. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor T-cell Therapy Discovery Approaches. Cell Rep. 2017; 19[13]:2509-2518.
Zhang X, Yang Y, Fan D, et al. Comparison of non-viral genome editing of CAR-T cells by mRNA electroporation and high-pressure nucleofection. Gene Ther. 2019;26[6]:262-271.
Ren J, Zhao Y. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell. 2017;8[10]:634-643.
Giordano Attianese GM, Marin V, Hoyos V, et al. In vivo validation of DNMT1 as a new target for the treatment of AML. Blood. 2018;132(22):2409-2409.
Schuster, S. J., et al. (2017). Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 9(375), eaaj2013.
Porter, D. L., et al. (2015). Chimeric Antigen Receptor T Cells Persist and Induce Sustained Hematological Malignancy Remission in Relapsed/Refractory Chronic Lymphoid Leukemia. Blood, 124(21), 377-377.
Turtle, C. J., et al. (2017). Long-Term Follow-up of a Phase 1 First-in-Human Study of CD19 CAR-T Cells: Activity and Tolerance of a Persistent Engineered T Cell Product. Blood, 128(22), 376-376.
Sadelain, M., et al. (2017). CAR-T-cell Therapy for Solid Tumors. American Society of Clinical Oncology Educational Book, 366-372.
Zhang, C., et al. (2019). Chimeric antigen receptor-engineered T-cell therapy for solid tumors. Molecular Cancer, 18(1), 1-14.
Ritchie, D., et al. (2017). Chimeric antigen receptor T cells targeting the immunodominant leukocyte antigen-1 epitope mediate potent antitumor activity against melanoma. European Journal of Immunology, 47(10), 1838-1849.
Hodi, F. S., et al. (2018). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363(8), 711-723.
Klapper, J. A., et al. (2016). Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer: From Bench to Bedside. Annual Review of Immunology, 34(1), 95-112.
Kershaw, M. H., et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research, 12(20), 6106-6115.
Chmielewski, M., et al. (2012). Ab CAR T cells targeting HER2/neu exhibit potent tumor lysis activity in vivo. Breast Cancer Research and Treatment, 135(2), 417-424.
Yang, S., et al. (2019). B7-H3 as a novel CAR-T therapeutic target for solid tumors. Journal of Hematology & Oncology, 12(1), 1-12.
Zhang, E., et al. (2017). Anti-MUC16 antibody-based chimeric antigen receptor T cells.
Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124[3]:188-95.
Kulemzin SV, et al. CAR T-cell therapy: balance between efficacy and safety. EJIFCC. 2019;30[3]:192-207.
Liu X, et al. Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Transl Pediatr. 2019;8[4]:258-265.
Zhang C, et al. Challenges and potential opportunities of CAR-T cell therapy in hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2019;8[4]:258-270.
Wang X, et al. Genome engineering of hematopoietic stem cells for cancer immunotherapy. Sci China Life Sci. 2019; 62[4]:365-375.
Iyer V, et al. Off-target mutations are rare in Cas9-modified mice. Nat Methods. 2015;12[7]:479.
Ramakrishna S, et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 2014;24[7]:1020-1027.
Tabebordbar M, et al. Efficient in vivo base editing in adult dystrophic mice. Nat Biotechnol. 2016;34(7): 810-815.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
